Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Next Previous
Trial Profile

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Casdatifan (Primary) ; Volrustomig (Primary) ; Zimberelimab (Primary)
  • Indications Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms ARC-20; eVOLVE
  • Sponsors Arcus Biosciences

Most Recent Events

  • 01 Jun 2025 Results presented in an Arcus Biosciences Media Release.
  • 01 Jun 2025 According to an Arcus Biosciences media release, data from this study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 06 May 2025 According to an Arcus Biosciences media release, company announced that more mature data from the casdatifan plus cabozantinib cohort and initial data from the new ARC-20 cohorts evaluating casdatifan in the first-line (1L) is ecpected in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top